MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
0.9801
+0.0026
+0.27%
Pre Market: 0.9999 +0.0198 +2.02% 07:52 07/01 EDT
OPEN
0.9700
PREV CLOSE
0.9775
HIGH
1.010
LOW
0.9433
VOLUME
358
TURNOVER
0
52 WEEK HIGH
2.570
52 WEEK LOW
0.8251
MARKET CAP
64.05M
P/E (TTM)
-1.0237
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TCRX last week (0622-0626)?
Weekly Report · 2d ago
TScan Therapeutics to join H.C. Wainwright Cell Therapy Virtual Conference fireside chat
PUBT · 06/24 11:01
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS)
TipRanks · 06/23 12:30
TScan Therapeutics Price Target Maintained With a $5.00/Share by Wedbush
Dow Jones · 06/23 12:30
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target
Benzinga · 06/23 12:20
TScan Therapeutics Price Target Maintained With a $6.00/Share by Needham
Dow Jones · 06/23 11:52
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target
Benzinga · 06/23 11:43
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (TCRX), Exelixis (EXEL) and AbbVie (ABBV)
TipRanks · 06/23 11:20
More
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.